Brown, Lisle/Cummings’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.3K | Buy |
293
+1
| +0.3% | +$38 | ﹤0.01% | 490 |
|
|
2025
Q1 | $11.3K | Sell |
292
-308
| -51% | -$11.9K | ﹤0.01% | 481 |
|
|
2024
Q4 | $20.3K | Hold |
600
| – | – | 0.01% | 417 |
|
|
2024
Q3 | $24.5K | Sell |
600
-332
| -36% | -$13.6K | 0.01% | 369 |
|
|
2024
Q2 | $35.9K | Sell |
932
-1,044
| -53% | -$40.2K | 0.01% | 339 |
|
|
2024
Q1 | $84.7K | Sell |
1,976
-5,389
| -73% | -$231K | 0.03% | 252 |
|
|
2023
Q4 | $273K | Buy |
7,365
+238
| +3% | +$8.82K | 0.1% | 173 |
|
|
2023
Q3 | $258K | Sell |
7,127
-1,242
| -15% | -$45K | 0.12% | 160 |
|
|
2023
Q2 | $298K | Sell |
8,369
-870
| -9% | -$31K | 0.13% | 149 |
|
|
2023
Q1 | $329K | Buy |
9,239
+1,010
| +12% | +$35.9K | 0.17% | 131 |
|
|
2022
Q4 | $289K | Sell |
8,229
-1,741
| -17% | -$61.2K | 0.16% | 127 |
|
|
2022
Q3 | $293K | Buy |
9,970
+1,900
| +24% | +$55.9K | 0.17% | 121 |
|
|
2022
Q2 | $439K | Buy |
8,070
+14
| +0.2% | +$762 | 0.24% | 99 |
|
|
2022
Q1 | $439K | Buy |
8,056
+274
| +4% | +$14.9K | 0.21% | 109 |
|
|
2021
Q4 | $429K | Buy |
+7,782
| New | +$429K | 0.21% | 107 |
|